Product: Pemetrexed Disodium
Appearance: white or off white crystalline powder
Chemical Name:
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate
Assay : 99.50% min
Cas No.: 357166-30-4
M.F.: C20H33N5Na2O13
M.W.: 597.4813
Package: 0.5kg/bag or according to requirements
Usage: used for treatment of malignant pleural mesothelioma and locally-advanced and metastatic non-small cell lung cancer in combination with cisplatin.
Place of Origin: China (mainland)
Delivery Detail: for prompt shipment
|
Name: Pemetrexed
|
MF: C20H33N5Na2O13
|
Grade Standard: Medicine Grade
|
|
Purity : 99.50% min
|
CAS No. 357166-30-4
|
Type: Antineoplastic
|
|
M.W.: 597.4813
|
Place of Origin: China (mainland)
|
Packaging: 0.5kg/aluminium foil bag
|
Specifications: In-house Standard
General Info: In February 2004, the Food and Drug Administration approved pemetrexed for treatment of malignant pleural mesothelioma, a type of tumor of the lining of the lung, in combination with cisplatin. In September 2008, the FDA granted approval as a first-line treatment, in combination with cisplatin, against locally-advanced and metastatic non-small cell lung cancer (NSCLC) in patients with non-squamous histology. A Phase III study showed benefits of maintenance use of pemetrexed for non-squamous NSCLC. Activity has been shown in malignant peritoneal mesothelioma. Trials are currently testing it against esophagus and other cancers.
Pemetrexed Disodium's intermediates:
150399-23-8 165049-28-5 137281-39-1 155405-80-4